Results 121 to 130 of about 589,865 (354)
Emerging targets in human lymphoma: targeting the MYD88 mutation [PDF]
, 2016 B cell neoplasms co-opt the molecular machinery of normal B cells for their survival. Technological advances in cancer genomics has significantly contributed to uncovering the root cause of aggressive lymphomas, revealing a previously unknown link ...
Horikawa, Keisuke +2 more
core +1 more source
Characteristics and overall survival in patients with T1 melanoma: A nationwide matched cohort study
International Journal of Cancer, EarlyView.What's New? Thin cutaneous malignant melanoma has an excellent ten‐year melanoma‐specific survival of 93%–97%. Moreover, the incidence of melanoma is higher among individuals with high socioeconomic status, which may protect them from other diseases. This nationwide matched cohort study found that patients with thin cutaneous malignant melanoma have a ...
Ylva Naeser +4 more
wiley +1 more source
Primary T-Cell Non-Hodgkin Lymphoma of the Vagina
Case Reports in Obstetrics and Gynecology, 2015 The primary vaginal T-cell non-Hodgkin lymphoma is a rare form of lymphoma. Most of the previously published cases were about B-cell non-Hodgkin lymphomas. We present the case of a vaginal mass in an 82-year-old patient presenting vaginal bleeding.
J. L. Herraiz +5 more
doaj +1 more source
Sustained delivery and molecular targeting of a therapeutic monoclonal antibody to metastases in the central nervous system of mice. [PDF]
, 2019 Approximately 15-40% of all cancers develop metastases in the central nervous system (CNS), yet few therapeutic options exist to treat them. Cancer therapies based on monoclonal antibodies are widely successful, yet have limited efficacy against CNS ...
Chen, Irvin SY +17 more
core
International Journal of Cancer, EarlyView.What's New? The understanding of the epidemiological and clinical distinctions between Epstein–Barr virus (EBV)‐positive and EBV‐negative classic Hodgkin lymphoma remains incomplete. Here, the authors generated unique sets of population‐based sex‐ and age‐specific incidence rates of classic Hodgkin lymphoma in Denmark stratified by histological subtype
Klaus Rostgaard +18 more
wiley +1 more source
Results of longstanding, single-center trial for pediatric Hodgkin lymphoma treatment
, 2021 Т. Т. Валиев, E. S. Belyaeva
openalex +2 more sources
International Journal of Cancer, EarlyView.What's New? Increasing cancer incidence and mortality in low‐ and middle‐income countries has heightened concerns about limited resources and barriers to care. This challenge is particularly urgent in Sub‐Saharan Africa (SSA), where cancer rates are rising sharply. Here, data from population‐based cancer registries in nine SSA countries was assessed to
Tamara König +19 more
wiley +1 more source
Acta Medica Indonesiana, 2018 Hodgkin lymphoma is a cancer that can be cured using standard chemotherapy with or without radiation. Although it accounts for only 0.6% of all malignancy worldwide, but it usually affects young adults with median age of 38 years.
Ikhwan Rinaldi
doaj +2 more sources
The Role of CD-19 Targeting Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin Lymphoma
High Yield Medical ReviewsChimeric Antigen Receptor (CAR) T-cell therapy has improved outcomes in multiple hematological malignancies, such as multiple myeloma and non-Hodgkin lymphoma.
Emaan Haque +4 more
doaj +1 more source
Tandem versus single haematopoietic stem cell transplant and
, 2023 Amira Marouf +17 more
openalex +1 more source